Agios Pharmaceuticals (AGIO) Receivables - Other (2016 - 2025)
Agios Pharmaceuticals (AGIO) has disclosed Receivables - Other for 12 consecutive years, with $10.6 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Receivables - Other rose 157.41% year-over-year to $10.6 million, compared with a TTM value of $10.6 million through Dec 2025, up 157.41%, and an annual FY2025 reading of $10.6 million, up 157.41% over the prior year.
- Receivables - Other was $10.6 million for Q4 2025 at Agios Pharmaceuticals, up from $5.0 million in the prior quarter.
- Across five years, Receivables - Other topped out at $10.6 million in Q4 2025 and bottomed at $1.2 million in Q3 2023.
- Average Receivables - Other over 5 years is $4.1 million, with a median of $3.6 million recorded in 2024.
- The sharpest move saw Receivables - Other plummeted 80.35% in 2022, then skyrocketed 165.14% in 2024.
- Year by year, Receivables - Other stood at $7.0 million in 2021, then tumbled by 68.44% to $2.2 million in 2022, then grew by 27.38% to $2.8 million in 2023, then soared by 46.23% to $4.1 million in 2024, then soared by 157.41% to $10.6 million in 2025.
- Business Quant data shows Receivables - Other for AGIO at $10.6 million in Q4 2025, $5.0 million in Q3 2025, and $5.0 million in Q2 2025.